Notably, the proteasome inhibitor, bortezomib, and the histone deacetylase (HDAC) inhibitor, romidepsin, showed a more remarkable antitumor effect in all five MFS cell lines than doxorubicin, which is used as a standard drug for the treatment of sarcomas (Figure 5, Table 3). The gene discussed is HDAC9; the disease is sarcoma.